CSL (ASX: CSL) A specialty biotherapeutics company







Product / Service

  • Biotherapeutics are therapeutic materials produced using biological means.  This includes recombinant DNA technology, the combination of DNA molecules from two different species inserted into a host organism to produce new genetic combinations

  • CSL’s biotherapies help people with life-threatening medical conditions

  • CSL operates three business units

  • CSL Behring – Plasma Products

    • Manufactures and markets a range of blood related therapies, including treatments for bleeding disorders and immune deficiencies.  Products are used in cardiac surgery, organ transplantation and victims of trauma, shock and burns

    • CSL Plasma is a division of CSL Behring and operates a large plasma collection network throughout the US and Europe

  • Seqirus (formerly bioCSL) – Vaccines & Pharmaceuticals

    • Manufactures seasonal and pandemic influenza vaccines for global markets

    • Markets and distributes vaccines and specialty pharmaceuticals in Australia and NZ

    • Develops, manufactures and markets diagnostic immunohaematology (more commonly known as blood banking – preparing blood and blood components for transfusion) reagents for Australia and Asia Pacific

    • Manufactures and distributes antivenoms and Q fever vaccine in Australia

    • Operates cold-chain logistics business for distribution of vaccines and prescription medicines in Australia

  • CSL Intellectual Property

    • Development of protein-based medicines to treat serious human illnesses  

    • Most medicines are purified from human plasma or using recombinant biotechnology

    • CSL employs 1,100 R&D experts around the world


  • As a result of World War I, in 1915 the Australian Government realised that it could no longer rely on overseas sources of medicines  

  • In response, the Government established the Commonwealth Serum Laboratories (CSL) in 1916  

  • On 25 April 1916, CSL began preparations of vaccines, serums and anti-toxins

  • CSL was privatised and listed on the ASX in 1994
  • For a detailed historical account, click here for CSL's: 100 Years Booklet 


  • Demand for CSL’s products ultimately comes from patients


  • The company is headquartered in Melbourne

  • The company’s manufacturing operations are in the US, UK, Germany, Switzerland and Australia

Committed to saving lives and improving the quality of life for people with bleeding disorders 

Profitability Table

Year Revenue ($m) % change NPBT ($m) % change
FY 2009 5,039 32.5 1,370 43.9
FY 2010 4,627 (8.2) 1,379 0.7
FY 2011 4,228 (8.6) 1,167 (15.4)
FY 2012 4,814 13.9 1,270 8.8
FY 2013 5,130 6.6 1,461 15.0
FY 2014 5,524 7.7 1,604 9.8
FY 2015 5,628 1.9 1,714 6.9
FY 2016 6,129 8.9 1,556 (9.2)

Fun Facts

  • Paul Perreault’s (CEO) total remuneration for FY 2016 was US$8.1m



Was this report helpful?
What can we do to improve?
Your email (optional)